Photodynamic drug therapy prevents restenosis:
This article was originally published in Clinica
The first few patients treated with a new photodynamic therapy for reducing restenosis of vessels following angioplasty showed no levels of clinically significant restenosis, according to six-month angiographic follow-up. Of eight lesions (seven patients) treated with Levulan (aminolevulinic acid HC1, DUSA Pharmaceuticals), three showed no evidence of restenosis; three had 25% restenosis; and two had 40% restenosis. The results of the pilot study, from the University College Hospitals in London, UK, were reported in the October issue of the British Journal of Surgery.
You may also be interested in...
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.